ADAMTS-12: A Multifaced Metalloproteinase in Arthritis and Inflammation

Jianlu Wei, 1,2 Brendon Richbourgh, 1 Tanghong Jia, 2 and Chuanju Liu 1,3

1 Department of Orthopaedic Surgery, New York University Medical Center, New York, NY 10003, USA
2 Department of Orthopaedic Surgery, Shandong University, Jinan, Shandong 250012, China
3 Department of Cell Biology, New York University School of Medicine, New York, NY 10016, USA

Correspondence should be addressed to Tanghong Jia; 370829625@qq.com and Chuanju Liu; chuanju.liu@nyumc.org

Received 15 January 2014; Revised 28 March 2014; Accepted 7 April 2014; Published 28 April 2014

1. Introduction

A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family consists of a precisely ordered modular organization that includes at least one thrombospondin type I repeat [1]. This family is thought to be comprised of a zinc-dependent group of proteases, which play vital roles in a variety of normal and pathological conditions [2–7]. ADAMTS family was first identified in 1997 [8]. Since that time the ADAMTS family has grown to include 19 members, which are involved in a plethora of diseases ranging from arthritis to coagulation disorders [1, 9–19]. The ADAMTS family is divided into four subgroups based on their structural and functional similarities [8, 20–22]. ADAMTS-17 and -19, ADAMTS-16 and -18, ADAMTS-7 and -12, and ADAMTS-6 and -10 compose the structurally related ADAMTS pairs division. ADAMTS-12 was first reported by Cal et al. in 2001 [23]. It has been well established that the ADAMTS-12 gene is expressed in the musculoskeletal system (skeletal muscles, cartilage, and tendons) and in the fetal lung [1, 23, 24]. There has been increasing evidence pertaining to the pathological relevance of this enzyme. For instance, ADAMTS-12 has been proven to be associated with the pathogenesis of arthritis [8–16], intervertebral disc degeneration [25, 26], inflammation [27, 28], and invasion and metastasis of tumor [29–31]. Although ADAMTS-7 and -12 share similar structure and domain organization, ADAMTS-7 and -12 may have different pathological effects or be responsible for different phases in a disease [26, 32]. For instance, ADAMTS-7 mRNA is found to be significantly increased in the cartilage of patients with rheumatoid arthritis (RA) and only slightly increased in the cartilage of patients with osteoarthritis (OA), whereas ADAMTS-12 mRNA is significantly increased in both OA and RA cartilage [10, 32]. Moreover, in intervertebral disc degenerative (IVD) rat model, the level of ADAMTS-7 was significantly increased in the early phase while the level of ADAMTS-12 was increased in the latter phase [26]. In this review, we will discuss the structure and perspective of ADAMTS-12 and focus on its roles and the underlying mechanisms in arthritis (especially osteoarthritis) and other diseases, including inflammation, tumorigenesis and antiangiogenesis, intervertebral disc degenerative disease, schizophrenia, gonad differentiation, trophoblast invasion, and pediatric stroke (Figure 1). In addition, we used
The impact of arthritic conditions is expected to grow as the elderly population increases in the coming decades [39, 40]. Osteoarthritis (OA) and rheumatoid arthritis (RA) are the most common categories of arthritis [8, 41–43]. OA is associated with age-related loss of homeostatic balance between degradation and repair mechanisms in articular cartilage, which is characterized by synovitis, cartilage degeneration, and osteophyte formation [44–47]. RA is a multifactorial disorder which can be affected by genetic alternation, inflammation, mechanical stress, obesity, and aging as well as biochemical, molecular, and enzymatic factors [48–51]. RA is a chronic systemic inflammatory disease that is characterized by the inflammatory proliferation of synovial tissues, leading to cartilage and bone damage and eventual disability [52–54]. Both genetic and environmental factors, as well as aberrant immune responses, play a key role in the pathogenesis of RA [55, 56]. The dysregulation in both OA and RA induces senescence, differentiation, proliferation, and cell death in joint cells through gene and/or protein expression networks that switch from anabolic to catabolic outcomes [48]. Recent evidence has demonstrated the significance of proteases, in the pathological processes of arthritis [57–59]. The destruction of the extracellular matrix of articular cartilage and bone in arthritic joints is thought to be mediated by excessive proteolytic activity [60]. In accordance with this concept, recent studies show that ADAMTS-12 also plays a critical role in the pathological process of arthritis [8, 32, 35, 43, 61].

ADAMTS12 and ADAMTS-12 as keywords to search articles through Pubmed, Google Scholar, and Web of Science.

2. Structural Organization of ADAMTS-12

The structure of ADAMTS-12 includes a signal peptide, a prodomain, a catalytic domain, a disintegrin-like domain, a central thrombospondin I (TS) repeat, a cysteine-rich domain, two spacer regions, and C-terminal TSP-like repeat region (Figure 2) [33, 34]. It was believed that the C-terminal tail of ADAMTS-12 might be important for the ability of ADAMTS-12 binding to the components of extracellular matrix (ECM). Indeed, it was found that the four TSP-like repeat regions of ADAMTS-12 directly bound to the EGF-like domain of cartilage oligomeric matrix protein (COMP) [1]. It was also reported that the C-terminal four TSP-like repeat inhibited chondrocyte differentiation [35]. To determine the effects of each functional domain of ADAMTS-12 on chondrocyte differentiation, numerous deleted mutants were generated, such as the removal of C-terminal four thrombospondin motifs known to bind COMP, the removal of a spacer-1 domain, the deletion of three thrombospondin motifs, and the deletion of a spacer-1 domain. All of the above mentioned deletions did not change the cell surface localization of the protein in chondrocytes. However, the deletion of the cysteine-rich domain released the enzyme from cell surface into the medium. These data indicated that the cysteine-rich domain of ADAMTS-12 was required for its binding to ECM and cell surface appearance in chondrocytes [35]. In addition, the antiangiogenesis properties of ADAMTS-12 did not rely on the catalytic domain, but, more likely, on its TSP-1 domains [30]. In contrast, the catalytic activity was implicated in the protective effect against allergen-induced inflammation [28].

3. Biological Functions of ADAMTS-12

3.1. Arthritis. Arthritis is the leading cause of physical disability, health care usage, and impaired quality of life [36–38]. The impact of arthritic conditions is expected to grow as the
The expression of ADAMTS-12 in the course of chondrogenesis was regulated by c-Maf transcription factor [72]. c-Maf, the cellular homologue of the avian viral oncogene c-Maf, was a member of the basic leucine zipper (bZIP) superfamily [73–75]. c-Maf proteins bind to a specific DNA sequences termed the “Maf recognition element” (MARE) through the basic DNA recognition domain [76]. In addition, c-Maf was overexpressed during embryonic development and postnatal growth in hypertrophic chondrocytes as well as in the osteoarthritic chondrocytes, which was similar to the expression pattern of that of ADAMTS-12 [73–75]. c-Maf and ADAMTS-12 were coexpressed in the process of in vitro chondrogenesis. Furthermore, c-Maf transcriptional factor directly binds to the proximal MARE sequences of ADAMTS-12 at position -61 in vitro [72].

Interestingly, ADAMTS-12 was found to function as the downstream target of parathyroid hormone-like hormone/parathyroid hormone related peptide (PTHLH/PTHrP) in chondrocytes, and both PTHLH and ADAMTS-12 were all downregulated along with impaired chondrogenic differentiation within brachyactyly type E (BDE) [77]. BDE is an autosomal-dominant disease characterized by bilateral anodontia, spaced teeth, and/or phalanges [78–80]. Additionally, PTHLH and both of its targets, ADAMTS-7 and -12, were downregulated in the fibroblasts of BDE patients. Furthermore, the expressions of chondrogenic markers (aggrecan, collagen II, collagen X, and Indian hedgehog (IHH)) in chondrogenically differentiated BDE were all significantly altered. These findings suggested that the expression of ADAMTS-12 and ADAMTS-7 are required for limb development.

Collectively, ADAMTS-12, whose expression was regulated by c-Maf transcription factor, acted as a downstream molecule of PTHrP signaling, negatively regulated chondrocyte differentiation, and hypertrophy (Figure 3). In addition, proper expression of ADAMTS-12 is required for normal cartilage development and its dysregulation may lead to pathologies with defects in the musculoskeletal system, such as BDE. Abnormal level and/or function of ADAMTS-12 may induce dysregulation of cartilage, which finally leads to arthritis.

ADAMTS-12's involvements in osteoarthritis is most probably due to its association and degradation of cartilage oligomeric matrix protein (COMP) [1, 8, 32, 67–71]. COMP, a prominent noncollagenous component of cartilage, accounts for approximately 1% of the wet weight of the tissue. The function of COMP may be involved in stabilizing cartilage ECM via specific interactions with matrix components such as collagen types II and IX, aggrecan, and fibronectin [81–83]. COMP also has a role in mediating chondrocyte attachment via an integrin receptor [84–87]. It was reported that mutations in the type III or C-terminal globular domain of the human COMP gene have been linked to the development of pseudoachondroplasia and multiple epiphyseal dysplasia, which were autosomal-dominant forms of short-limb dwarfism [88, 89]. COMP fragments have been detected in the diseased cartilage, synovial fluid, and serum of patients with knee injuries [90]. The level of ADAMTS-12 was significantly increased in the cartilage and synovium of patients with RA or OA [9, 10]. Both the in vitro glutathione S-transferase (GST) pull-down assay and coimmunoprecipitation assay demonstrated that ADAMTS-12 could bind to COMP directly [1]. Importantly, the size of COMP fragments generated by ADAMTS-12 was similar to those of COMP-degraded fragments seen in arthritic patients [43]. In addition, antibodies against ADAMTS-12 dramatically inhibited tumor necrosis factor-induced (TNF-induced) and interleukin-1β-induced (IL-1β-induced) COMP degradation in cartilage explants [43]. Suppression of ADAMTS-12 expression using the small interfering RNA silencing approach in human chondrocytes also markedly prevented COMP degradation. In addition, ADAMTS-7 and -12 were colocalized with COMP both in the cytoplasm and on the surface of human chondrocytes [25, 35]. While ADAMTS-7 was unable to digest aggrecan [91], ADAMTS-12, with a similar structure, did have the ability to digest aggrecan [5].

It was reported that alpha-2-macroglobulin (α2 M) acted as a substrate for both ADAMTS-7 and ADAMTS-12 and efficiently protected COMP degradation by these enzymes by in vitro digestion assays [43]. In addition, granulin-epithelin precursor (GEP, a newly identified chondrogenic growth factor, which was also known as proepithelin, acrogranin, progranulin (PGRN), and GP88/PC cell-derived growth factor) inhibited the action of ADAMTS-12 preventing COMP degradation via two distinct mechanisms [61, 92–97]. In detail, GEP inhibits the induction of ADAMTS-12 by inflammatory cytokines such as TNF-α and GEP is able...
Mediators of Inflammation

4

Figure 3: Regulation of ADAMTS-12 by PTHrP signaling in chondrocyte differentiation. ADAMTS-12 acts as a downstream molecule of PTHrP/PTHLH signaling and is regulated by c-Maf transcription factor in the course of chondrogenesis. Abbreviations: PTHrP/PTHLH: parathyroid hormone-like hormone; ADAMTS: a disintegrin and metalloproteinasewith thrombospondin motifs.

to disrupt the association between ADAMTS-12 and COMP via a direct protein-to-protein interaction [8, 61]. It was approved that ADAMTS-12, COMP, aggrecan, GEP, α2M, and TNF-α constitute an interplay and interaction network in mediating cartilage degradation in arthritis (Figure 4). TNF-α upregulates ADAMTS-12 leading to the degradation of COMP [43, 98, 99]. In addition, TGF-β was reported to significantly induce the ADAMTS-12 in human fetal fibroblasts [21]. This in vitro data provide insight into the critical role of ADAMTS-12 in the initiation and progression of osteoarthritis which needs to be further confirmed using in vivo genetically modified animal models. Interestingly, such in vivo models for ADAMTS-7, which shares similar domain organization and structure, have been generated, and the critical role of ADAMTS-7 in the pathogenesis of OA has been elucidated [58].

It was reported that ADAMTS-7 formed a positive feedback loop with TNF-α in the pathogenesis of osteoarthritis [58]. ADAMTS-7 expression was elevated during disease progression in the surgically induced rat OA model. Targeted overexpression of ADAMTS-7 in chondrocytes led to chondrodysplasia characterized by short-limbed dwarfism and a delay in endochondral ossification in "young mice" and a spontaneous OA-like phenotype in "aged" mice. In addition, overexpression of ADAMTS-7 led to exaggerated breakdown of cartilage and accelerated OA progression, while knockdown of ADAMTS-7 attenuated degradation of cartilage matrix and protected against OA development, in surgically induced destabilization of medial meniscus OA models [58, 100]. ADAMTS-7 upregulated TNF-α and metalloproteinases associated with OA; in addition, TNF-α induced ADAMTS-7 through NF-κB signaling. These data indicated that ADAMTS-7 and TNF-α form a positive feedback loop in the regulation of cartilage degradation and OA progression [58, 101]. Aside from the fact that ADAMTS-12 shares a similar structure with ADAMTS-7, ADAMTS-12 may play a critical role in the OA development in vivo [10, 23, 58].

3.3. In Rheumatoid Arthritis. Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease, characterized by inflammation of the synovial membrane and progressive destruction of the articular cartilage and bone [102, 103]. As we have previously stated, ADAMTS-12 is an inflammation-related protein, which can digest COMP; it was reported that ADAMTS-12 might play a role in RA [104, 105]. ADAMTS-12 was recently identified as a susceptible gene for RA [104]. Three single nucleotide polymorphisms (SNPs) (rs1364044, intron C/T; rs10461703, intron C/T; rs25754, missense Thr1495Ile) of ADAMTS12 were genotyped by using a direct sequencing method in 303 RA patients and 495 control subjects. Multiple logistic regression models, SNPStats and SNPAnalyzer Pro programs, and Bonferroni’s correction (pc) were used and found that the genotype frequency of rs10461703 was associated with the RA development. However, no significant correlation was observed between the three tested SNPs and RA patients with regard to their clinical features [104].

Clinically, women are more susceptible to RA than men [105–107]. ADAMTS-12 was reported to associate with sex-specific disparities in RA resulting in cartilage degradation [105]. The involvement of sex chromosomes in RA and the relationship between animal models of RA and gender have been reported by several laboratories [108–114]. In addition,
Figure 4: The interplay network in the degradation of extracellular matrix mediated by ADAMTS-12 in arthritis. ADAMTS-12 mediated proteolysis of aggrecan and COMP is positively modulated by TNF-α and inhibited by α2M and GEP. Abbreviations: yellow arrows indicate a stimulatory effect; perpendicular lines indicate an inhibitory effect; α2M: alpha-2-macroglobulin; ADAMTS: a disintegrin and metalloproteinase with thrombospondin motifs; TNF: tumor necrosis factor; COMP: cartilage oligomeric matrix protein; GEP: granulin-epithelin precursor.

4. Other Conditions and Diseases

4.1. Inflammation. ADAMTS-12 has also been reported to be a critical mediator in inflammation, especially allergic inflammation [24, 27, 28]. ADAMTS-12 has been identified as one asthma-associated gene in the human genome screening program [24]. Asthma is characterized by a specific pattern of inflammation and airway/bronchial hyperresponsiveness (AHR/BHR) [118, 119]. Fine mapping and positional candidate studies were performed in the Hutterites (South Dakota) and an outbred case-control sample from Germany [24]. Genotyping on chromosome 5p showed that SNPs in ADAMTS-12 were primarily associated with bronchial hyperresponsiveness (BHR) in the Hutterites. In addition, variation of ADAMTS-12 was also associated with asthma in the outbred Germans. Furthermore, there was a significant difference between asthma cases and controls in the frequencies of long range haplotypes composed of SNPs at ADAMTS-12 [24].

Recently, asthma OVA and HDM model were generated in the ADAMTS-12-deficient mice to determine the role of ADAMTS-12 in this disease [28]. It was found that ADAMTS-12 deficiency could exacerbate an allergen-induced inflammatory and airway response by inducing Th2 inflammation [28]. ADAMTS-12-deficient mice models displayed a more severe phenotype of allergen-induced AHR when compared to their corresponding WT littermates by histological analysis. In addition, the markers of Th2-skewed inflammatory response, such as Ag-specific IgE and Ag-specific IgG1, were all significantly increased in allergen-induced mice. And there appeared to be no difference between the groups when evaluating the Th1-associated marker, IgG2a. The cytokine levels of IL-4 and IL-13 (typical Th2 cytokines) were highly increased in ADAMTS-12-deficient mice. On the other hand, the levels of IL-10 and IFN-γ (Th1 cytokines) did not exhibit significant changes. Furthermore, the levels of RANTES (CCL5) (a major eosinophil chemoattractant [120]), IL-5 (known to regulate eosinophil differentiation and survival [121]), and IL-33 (known to further contribute to exacerbated eosinophil [122, 123]) were all increased and coordinate with the increased amount of eosinophilia. IL-33 could most notably increase mast cell recruitment through ST2 receptor activation. The levels of both the mast cells and ST2 receptor were higher within the lungs of allergen-induced ADAMTS-12-deficient mice [124, 125].

In addition to its involvements in allergic inflammation, ADAMTS-12 was found to be required in normal inflammation [27]. To elucidate the role of ADAMTS-12 in normal inflammation, several in vivo murine models have been studied. ADAMTS-12-deficient mice were used to create the animal models for colitis, endotoxic sepsis, and pancreatitis [27]. ADAMTS-12-deficient mice exhibited more severe inflammation. They also experienced a delay in the recovery process from these challenges by comparison with their wild-type littermates. The ADAMTS-12-deficient tissues showed a significant increase in several inflammatory markers in both RNA and protein levels after analysis. In addition, all ADAMTS-12-deficient mice models exhibited severe inflammatory symptoms accompanied by neutrophilia.
in the affected tissues. ADAMTS-12 exhibited a protective role in inflammatory pathogenesis [27]. ADAMTS-12 achieved this by inducing the apoptosis of neutrophils. Furthermore, hemopexin and cytokines such as granulocyte colony stimulating factor (GCSF) and IL-6 were increased in the ADAMTS-12-deficient mice. Notably, hemopexin and GCSF had the ability to promote duration and inhibit the apoptosis of neutrophils [126–128]. IL-6 was also reported to function as compensation for limiting neutrophils recruitment [129].

Above all, ADAMTS-12 has a genetic linkage with asthma and a deficiency in ADAMTS-12 leads to defects in both the normal and hyperresponsive inflammatory response. It may act as an important mediator maintaining the immune balance in both biological and pathological process. Clearly, the molecular events and mechanisms underlying ADAMTS-12-mediated regulation of inflammation warrant further investigations.

4.2. IVD Degeneration. Within intervertebral disc (IVD) degeneration the subchondral endplate condenses to a denser structure. This process may negatively influence both the diffusion and nutrition of the IVD, which can lead to a more severe phenotype. It was reported that the expressions of ADAMTS-7 and ADAMTS-12 in the endplate cells isolated from patients with degenerative disc disease were significantly increased [25]. A rat caudal intervertebral disc model was used to examine the expression profiling of ADAMTS-7 and -12 in the course of the degeneration of intervertebral disc [26]. ADAMTS-7 and ADAMTS-12 were detected in the NPs and their expressions were slightly changed within the first 18 hours after loading. After that window of time both ADAMTS-7 and -12 increased significantly and coordinated with the dramatic increase of COMP. Within a recent load-induced IVD degenerative rat model, the expression of ADAMTS-7 peaked on the first day and ADAMTS-12 expression reached peak level on the 7th day. However, on 7th day, the level of ADAMTS-12 was much higher than that of ADAMTS-7. This data suggests that ADAMTS-7 and ADAMTS-12 may contribute to the early and late degeneration stage of IVD, respectively [26].

4.3. Tumor Suppression and Angiogenesis Inhibition. ADAMTS-12 was found to be expressed in the fibroblasts adjacent to the tumor cells in the colorectal cancer specimens from human patients [31]. In addition, the expression of ADAMTS-12 was not associated with the tumor origin, nor gender or age, but depended on the differentiation of the cancer cells. Well-differentiated cells exhibited a higher staining score while poorly differentiated cells displayed negative staining. Moreover, the ADAMTS-12 expression in cancer stroma of patients with lymph node metastasis was greater than that within the patients without lymphatic metastasis. Therefore, ADAMTS-12 may be a promising prognostic indicator for colorectal cancer [31].

The actual secretion of ADAMTS-12 was lost by the epigenetic silencing in tumor cells [130]. This silencing occurs in a compensatory manner within induced stromal cells. The ADAMTS-12 gene promoter was hypermethylated in colorectal carcinomas and colon cancer cell lines resulting in colorectal carcinomas and colon cancer cell lines retaining the silence of ADAMTS-12 expression [29]. In addition, it was reported that ADAMTS-12 was expressed in fibroblastic-like cells surrounding malignant cells [29], and it was confirmed by histological staining from clinic [31]. Moreover, well and moderately differentiated carcinomas showed a strong immunoreactivity for ADAMTS-12 whereas poorly differentiated cells showed weak staining. The expression of ADAMTS-12 was doubled when fibroblasts coculture with colon cancer cells compared with fibroblasts cultures alone. It has been documented that the tumor cell growth rate was significantly decreased when fibroblasts coculture with colon cancer cells, as compared to colon cancer cell cultures alone. Furthermore, the apoptotic cancer cell population of cocultured cells with colon fibroblasts was much higher than that of tumor cell cultures alone. It was reported that fibroblasts-expressed ADAMTS-12 acted as a compensatory strategy for the epigenetic silencing of this gene within malignant cells.

ADAMTS-12 was reported to exact an tumorigenesis and angiogenesis-inhibitory effect [5, 29–31, 131]. ADAMTS-12 was found to play a protective role in angiogenesis and cancer progression via using ADAMTS-12-deficient-mice models [30]. Malignant keratinocyte (PDVA cell line) transplanted demonstrated that tumor vascularization and invasion were increased in ADAMTS-12-deficient-mice. In addition, this observation was also confirmed by a computerized image analysis [132]. The aortic explants assay and basic fibroblast growth factor (bFGF) injection indicated that ADAMTS-12 was a negative regulator of angiogenesis [133]. Additionally, the overexpression of ADAMTS-12 in breast carcinoma (MCF7 cell line) resulting in reduced new vessel formation exhibited an inhibitory effect in angiogenesis as well [30]. ADAMTS-12 was also found to abolish vascular endothelial growth factor- (VEGF-) induced tube formation in the bovine aortic endothelial (BAE) cells [5]. Furthermore, ADAMTS-12 inhibited tumor growth in vivo as well, since injection of A549 cells overexpressing ADAMTS-12 into the immunodeficient-SCID-mice showed a reduced tumor growth [5].

ADAMTS-12 was reported to play its tumorigenesis role by modulating the Ras-dependent ERK signaling pathway [5]. There was a notable lower level of phosphorylated ERK in the Madin-Darby canine kidney (MDCK) cells expressing ADAMTS-12 than those lacking ADAMTS-12 after being stimulated by hepatocyte growth factor (HGF) [5]. In addition, ADAMTS-12 may function as a tumor suppressor through limiting the proliferation of tumor cells [29]. Interestingly, the catalytic activity of ADAMTS-12 appeared to be dispensable for its angiogenic-inhibitory function, since the mutations in the catalytic domain inactivated its enzymatic activity but did not impair the antiangiogenic effect [30].

New findings have illustrated that ADAMTS-12 could elicit tumorigenesis effects when it interacts with fibulin-2 in breast cancer [131]. Fibulin-2 belongs to fibulins, which are components of basement membranes and elastic matrix fibers in connective tissue and also play a role in tumorigenesis [134–136]. Both in vitro and in vivo data have
shown that ADAMTS-12 itself could exhibit protumor effect while interaction of ADAMTS-12 and fibulin-2 could exhibit tumorigenesis effect [131]. Furthermore, clinically detection of both proteins in breast cancer patients predicted a good prognosis [131].

Taken together, both in vivo and in vitro experiments demonstrate that ADAMTS-12 expression associates with the differentiation of the cancer cells and has tumorigenesis and antiangiogenic effects. Thus, ADAMTS-12 may provide a new molecular target for treating various types of cancer in addition to the potential of being employed as a prognostic indicator in tumor malignant grade and metastasis.

4.4. Schizophrenia. Members of ADAMTS family have been implicated in neurodegenerative and neuroinflammatory diseases [137–139]. In addition, some metalloproteinases, including MMP-9 and ADAMTSL3, were found to be implicated in schizophrenia [140, 141]. Recently ADAMTS-12 was also reported to have an association with schizophrenia [142]. The ADAMTS-12 gene had been shown to be a functional and positional candidate in the susceptibility of schizophrenia by mutation analysis in Puerto Rican patients of Spanish descent. Moreover, the intronic variant rs256792 and the two-SNP haplotype rs256603–rs256792 were closely associated with the disorder, although the function of single nucleotide polymorphisms remains largely unknown.

4.5. Gonad Differentiation. ADAMTS-12 was recently isolated as a gene involved in the gonadal development [143]. Briefly, 110 genes were selected for evaluation of their expression during chicken gonad differentiation, and ADAMTS-12 showed higher level of expression within the testis and was increased during gonadal development [143]. Furthermore, whole mount in situ hybridization assay revealed that ADAMTS-12 was expressed in the testis on day 7, the time of histological differentiation of the gonads. In addition, ADAMTS-12 was located in the developing testicular cords. A previous study reported that ADAMTS-12 acted as an inhibitor of SOX9 expression during in vitro chondrocyte differentiation [143] and the reverse expression profiling between ADAMTS-12 and Sox9 in the course of chicken gonad differentiation indicating that ADAMTS12 may be a novel regulator of gonad differentiation through modulating SOX9 transcription factor. In addition, it was reported that ADAMTS-12 might be an early marker of male gonad differentiation [143].

4.6. Trophoblastic Cell Invasion. In addition to its potential role in male gonad differentiation, ADAMTS-12 was also found to be involved in the trophoblastic cell invasion [144, 145]. ADAMTS-12 was found to be detectable in samples of human placental tissue from the first trimester [145]. ADAMTS-12 altered the cell-extracellular matrix (ECM) interactions leading to the reduction of cell adhesion capability and promotion of cell invasion by measuring the first trimester trophoblastic cells. Expression of ADAMTS-12 was significantly higher in cultures of invasive extravillous cytotrophoblast (EVT) than in poorly invasive JEG-3 choriocarcinoma cells. ADAMTS-12 was found to promote cell invasion using both overexpression and siRNA knockdown assays. In addition, it was reported that gonadotropin-releasing hormone- (GnRH-) I and II increased ADAMTS-12’s expression in EVT within a time- and concentration-dependent manner [144] and transforming growth factor-β1 (TGF-β1) promoted cytotrophoblast invasion in vitro while interleukin-1β (IL-1β) restrained cytotrophoblast invasion in vitro [145]. In addition, ADAMTS-12 reduced cell-ECM adhesion by regulating the αvβ3 integrin heterodimer [145]. Furthermore, the ability of ADAMTS-12 to promote invasion largely depended on the disintegrin-like domain and ancillary domains [144].

4.7. Pediatric Stroke. It was reported that there was a relationship between the ADAMTS family and pediatric stroke [146]. Pediatric stroke was a heterogeneous disorder associated with significant morbidity and mortality. Although SNPs residing in ADAMTS12 were strongly associated with pediatric stroke [146], the mechanisms through which the genetic variants in ADAMTS genes lead to pediatric stroke still remain unknown.

5. Summary and Perspective

ADAMTS-12 protease is involved in the processes of chondrocyte differentiation and cartilage development. The dysregulation of ADAMTS-12 is associated with musculoskeletal degenerative diseases, including arthritis and IVD degeneration, which probably resulted from its degradation of COMP, aggrecan, and other unidentified matrix proteins and its role in inflammation. In addition, ADAMTS-12 functions as a protective mediator in both normal and hyperresponsive inflammation by inducing neutrophil apoptosis and interfering with the T response, respectively. Furthermore, ADAMTS-12 is found to exhibit tumorigenesis and angiogenic-inhibitory effect in certain cancer types and ADAMTS-12 has the potential to be used as an indicator of cancer prognosis. ADAMTS-12 also promotes the invasive ability of trophoblastic cells and acts as an early marker of male gonad differentiation in chicken.

Although growing evidence indicates that ADAMTS-12 is a metalloproteinase with multiple functions, the exact expression profiling, regulation, and function of ADAMTS-12 in various pathophysiological processes, especially the signaling pathways and molecular events involved, remain to be delineated. Moreover, the function of each domain should be taken into account since it has been reported that thrombospondin type 1 repeats interact with MMP-2, whose role in osteoarthritis is currently emerging [147]. By determining the functional domain of ADAMTS-12 in osteoarthritis, we can develop a more efficient inhibitor to rescue this disease. In addition, the protein partner of ADAMTS-12 in the progression of osteoarthritis is also a big challenge to us.

Although global knockout mice of ADAMTS-12 are viable, timely controlled (i.e., inducible), tissue-specific
knockout and/or transgenic mice are required for precisely dissecting the role of ADAMTS-12 in the development of various tissues. In addition, these mouse strains are especially useful for generating various kinds of diseases models. For instance, in order to figure out the potential effect of ADAMTS-12 in cartilage development and the initiation and/or progression of OA, cartilage specific deletion of ADAMTS-12 in the adult mice is required for generating surgically induced OA models.

**Abbreviations**

ECM: Extracellular matrix  
COMP: Cartilage oligomeric matrix protein  
ADAMTS: A disintegrin and metalloproteinase with thrombospondin motifs  
MMP: Matrix metalloproteinase  
IVD: Intervertebral disc  
PThhP/PTHHLH: Parathyroid hormone-like hormone  
MARE: Maf recognition element  
BDE: Brachyactly type E  
SNPs: Single nucleotide polymorphisms  
OA: Osteoarthritis  
RA: Rheumatoid arthritis  
CAIA: Collagen antibody-induced arthritis  
GEP: Granulin-epithelin precursor  
α2, M: Alpha-2-macroglobulin  
NP: Nucleus pulposus  
EVT: Extravillous cytotrophoblast  
GnRH: Gonadotropin-releasing hormone.

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**Acknowledgments**

C. J. Liu is grateful to his gifted collaborators who made the explorations in his laboratory possible. This work is supported partly by NIH research Grants R01AR062207, R01AR061484, and R56AI100901, Disease Targeted Research Grants from the American College of Rheumatology Research and Education Foundation.

**References**

[1] C.-J. Liu, W. Kong, K. Xu et al., “ADAMTS-12 associates with and degrades cartilage oligomeric matrix protein,” *Journal of Biological Chemistry*, vol. 281, no. 23, pp. 15800–15808, 2006.

[2] G. G. Levy, W. C. Nichols, E. C. Lian et al., “Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura,” *Nature*, vol. 413, no. 6855, pp. 488–494, 2001.

[3] D. R. Barreda, P. C. Hanington, C. K. Walsh, P. Wong, and M. Belosevic, “Differentially expressed genes that encode potential markers of goldfish macrophage development in vitro,” *Developmental and Comparative Immunology*, vol. 28, no. 7-8, pp. 727–746, 2004.

[4] S. Porter, I. M. Clark, L. Kevorkian, and D. R. Edwards, “The ADAMTS metalloproteinases,” *Biochemical Journal*, vol. 386, no. 1, pp. 15–27, 2005.

[5] M. Llamazares, A. J. Obaya, A. Moncada-Pazos et al., “The ADAMTS12 metalloproteinase exhibits anti-tumorigenic properties through modulation of the Ras-dependent ERK signalling pathway,” *Journal of Cell Science*, vol. 120, no. 20, pp. 3544–3552, 2007.

[6] R. Roy, G. Louis, K. R. Loughlin et al., “Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species,” *Clinical Cancer Research*, vol. 14, no. 20, pp. 6610–6617, 2008.

[7] A. Rowan, G. J. Litheral, W. Hu, and J. M. Miller, “Metalloproteases as potential therapeutic targets in arthritis,” *Expert Opinion on Therapeutic Targets*, vol. 12, no. 1, pp. 1–18, 2008.

[8] A. Little, “Drug Insight: aggrecanases as therapeutic targets in osteoarthritis,” *Arthritis Research and Therapy*, vol. 5, no. 1, pp. 131–141, 2004.

[9] G. C. Jones, A. G. Corps, C. J. Pennington et al., “Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage,” *Arthritis and Rheumatism*, vol. 50, no. 1, pp. 321–332, 2008.

[10] C.-J. Liu, W. Kong, K. Ilalov et al., “ADAMTS-7: a metalloproteinase that directly binds to and degrades cartilage oligomeric matrix protein,” *The FASEB Journal*, vol. 20, no. 7, pp. 988–990, 2006.

[11] A. D. Rowan, G. J. Litherland, W. Hui, and J. M. Milner, “Metalloproteases as potential therapeutic targets in arthritis treatment,” *Expert Opinion on Therapeutic Targets*, vol. 12, no. 1, pp. 1–18, 2008.

[12] G. Murphy and H. Nagase, “Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?” *Nature Clinical Practice Rheumatology*, vol. 4, no. 3, pp. 128–135, 2008.

[13] A. J. Fosang and C. B. Little, “Drug Insight: aggrecanases as therapeutic targets for osteoarthritis,” *Nature Clinical Practice Rheumatology*, vol. 4, no. 8, pp. 420–427, 2008.

[14] A. J. Fosang and C. B. Little, “Drug Insight: aggrecanases as therapeutic targets for osteoarthritis,” *Nature Clinical Practice Rheumatology*, vol. 4, no. 8, pp. 420–427, 2008.

[15] G. Murphy and M. H. Lee, “What are the roles of metalloproteinases in cartilage and bone damage?” *Annals of the Rheumatic Diseases*, vol. 64, supplement 4, pp. iv44–iv47, 2005.

[16] A. Borgi, N. Khemiri, A. Veyradier, K. Kazdaghi, and S. Barsaoui, “Congenital thrombotic thrombocytopenic purpura: atypical presentation and new ADAMTS 13 mutation in a Tunisian child,” *Mediterranean Journal of Hematology and Infectious Diseases*, vol. 5, no. 1, Article ID e2013041, 2013.

[17] Y. Chinen, J. Kuroda, M. Ohshiro et al., “Low ADAMTS-13 activity during hemorrhagic events with disseminated intravascular coagulation,” *International Journal of Hematology*, vol. 97, no. 4, pp. 511–519, 2013.

[18] P. J. Hosein, M. D. Craig, M. S. Tallman et al., “A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin’s and non-Hodgkin’s lymphoma,” *The American Journal of Hematology*, vol. 87, no. 1, pp. III–114, 2012.
[20] J. D. Thompson, D. G. Higgins, and T. J. Gibson, “CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice,” Nucleic Acids Research, vol. 22, no. 22, pp. 4673–4680, 1994.

[21] M. Llamazaes, S. Cal, V. Quesada, and C. López-Otin, “Identification and characterization of ADAMTS-20 defines a novel subfamily of metalloproteinases-disintegrins with multiple thrombospondin-1 repeats and a unique GON domain,” Journal of Biological Chemistry, vol. 278, no. 15, pp. 13382–13389, 2003.

[22] A. C. Nicholson, S.-B. Malik, J. M. Logsdon Jr., and E. G. van Meir, “Functional evolution of ADAMTS genes: evidence from analyses of phylogeny and gene organization,” BMC Evolutionary Biology, vol. 5, article 11, 2005.

[23] S. Cal, J. M. Argüelles, P. L. Fernández, and C. López-Otin, “Identification, characterization, and intracellular processing of ADAM-TS12, a novel human disintegrin with a complex structural organization involving multiple thrombospondin-1 repeats,” Journal of Biological Chemistry, vol. 276, no. 21, pp. 17932–17940, 2001.

[24] T. Kurz, S. Hoffjan, M. G. Hayes et al., “Fine mapping and positional candidate studies on chromosome 5p13 identify multiple asthma susceptibility loci,” Journal of Allergy and Clinical Immunology, vol. 118, no. 2, pp. 396–402, 2006.

[25] Q. Zhang, M. Huang, X. Wang, X. Xu, M. Ni, and Y. Wang, “Negative effects of ADAMTS-7 and ADAMTS-12 on endplate cartilage differentiation,” Journal of Orthopaedic Research, vol. 30, no. 8, pp. 1238–1243, 2012.

[26] H. Yu and Y. Zhu, “Expression of ADAMTS-7 and ADAMTS-12 in the nucleus pulposus during degeneration of rat caudal intervertebral disc,” Journal of Veterinary Medical Science, vol. 74, no. 1, pp. 9–15, 2012.

[27] A. Moncada-Pazos, A. J. Obaya, M. Llamazaes et al., “ADAMTS-12 metalloprotease is necessary for normal inflammatory response,” The Journal of Biological Chemistry, vol. 287, no. 47, pp. 39554–39563, 2012.

[28] G. Paulissen, M. El Hour, N. Rocks et al., “Control of allergen-induced inflammation and hyperresponsiveness by the metalloproteinase ADAMTS-12,” The Journal of Immunology, vol. 189, no. 8, pp. 4135–4143, 2012.

[29] A. Moncada-Pazos, A. J. Obaya, M. F. Fraga et al., “The ADAMTS12 metalloprotease gene is epigenetically silenced in tumor cells and transcriptionally activated in the stroma during progression of colon cancer,” Journal of Cell Science, vol. 122, no. 16, pp. 2906–2913, 2009.

[30] M. El Hour, A. Moncada-Pazos, S. Blacher et al., “Higher sensitivity of ADAMTS12-deficient mice to tumor growth and angiogenesis,” Oncogene, vol. 29, no. 20, pp. 3025–3032, 2010.

[31] D. Wang, T. Zhu, F.-B. Zhang, and C. He, “Expression of ADAMTS12 in colorectal cancer-associated stroma prevents cancer development and is a good prognostic indicator of colorectal cancer,” Digestive Diseases and Sciences, vol. 56, no. 11, pp. 3281–3287, 2011.

[32] C.-J. Liu, “The role of ADAMTS-7 and ADAMTS-12 in the pathogenesis of arthritis,” Nature Clinical Practice Rheumatology, vol. 5, no. 1, pp. 38–45, 2009.

[33] B. L. Tang, “ADAMTS: a novel family of extracellular matrix proteases,” International Journal of Biochemistry and Cell Biology, vol. 33, no. 1, pp. 33–44, 2001.

[34] K. Kuno, Y. Okada, H. Kawashima et al., “ADAMTS-1 cleaves a cartilage proteoglycan, aggrecan,” FEBS Letters, vol. 478, no. 3, pp. 241–245, 2000.

[35] X. H. Bai, D. W. Wang, Y. Luan, X. P. Yu, and C. J. Liu, “Regulation of chondrocyte differentiation by ADAMTS-12 metalloproteinase depends on its enzymatic activity,” Cellular and Molecular Life Sciences, vol. 66, no. 4, pp. 667–680, 2009.

[36] H. L. Brelan, “Self-reported arthritis burden and management in South Carolina,” Southern Medical Journal, vol. 106, no. 5, pp. 305–309, 2013.

[37] E. I. Enyinna, J. G. Anderson, E. I. Merwin, and A. G. Taylor, “Chiropractic use, health care expenditures, and health outcomes for rural and nonrural individuals with arthritis,” Journal of Manipulative and Physiological Therapeutics, vol. 35, no. 7, pp. 515–524, 2012.

[38] “Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation—United States, 2007–2009,” Morbidity and Mortality Weekly Report, vol. 59, no. 39, pp. 1261–1265, 2010.

[39] A. M. Taylor, “Metabolic and endocrine diseases, cartilage calcification and arthritis,” Current Opinion in Rheumatology, vol. 25, no. 2, pp. 198–203, 2013.

[40] A. M. Sanzone and R. E. Begue, “Hepatitis C and arthritis: an update,” Infectious Disease Clinics of North America, vol. 20, no. 4, pp. 877–889, 2006.

[41] L. Troebenberg and H. Nagase, “Proteases involved in cartilage matrix degradation in osteoarthritis,” Biochimica et Biophysica Acta, vol. 1824, no. 1, pp. 133–145, 2012.

[42] J. M. Kahlenberg and M. J. Kaplan, “Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus,” Annual Review of Medicine, vol. 64, pp. 249–263, 2013.

[43] Y. Luan, L. Kong, D. R. Howell et al., “Inhibition of ADAMTS-7 and ADAMTS-12 degradation of cartilage oligomeric matrix protein by alpha-2-macroglobulin,” Osteoarthritis and Cartilage, vol. 16, no. 11, pp. 1413–1420, 2008.

[44] M. K. Lotz and V. B. Kraus, “New developments in osteoarthritis,” Current Opinion in Rheumatology, vol. 12, no. 3, article 211, 2010.

[45] M. Hashimoto, T. Nakasa, T. Hikata, and H. Asahara, “Molecular network of cartilage homeostasis and osteoarthritis,” Medical Research Reviews, vol. 28, no. 3, pp. 464–481, 2008.

[46] M. B. Goldring and K. B. Marcu, “Cartilage homeostasis in health and rheumatic diseases,” Arthritis Research and Therapy, vol. 11, no. 3, article 224, 2009.

[47] J. H. Herndon, S. M. Davidson, and A. Apazidis, “Recent socioeconomic trends in orthopaedic practice,” Journal of Bone and Joint Surgery A, vol. 83, no. 7, pp. 1097–1105, 2001.

[48] S. Miyaki and H. Asahara, “Macro view of microRNA function in osteoarthritis,” Nature Reviews Rheumatology, vol. 8, no. 9, pp. 543–552, 2012.

[49] O. S. Atik, “Is subchondral bone the crucial point for the pathogenesis and the treatment of osteoarthritis?” Eklem Hastalıkları ve Cerrahisi, vol. 25, no. 1, p. 1, 2014.

[50] J. Martel-Pelletier and J.-P. Pelletier, “Is osteoarthritis a disease involving only cartilage or other articular tissues?” Eklem Hastalıkları ve Cerrahisi, vol. 21, no. 1, pp. 2–14, 2010.

[51] O. S. Atik, “Leukotriene B4 and prostaglandin E2-like activity in synovial fluid in osteoarthritis,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 39, no. 4, pp. 253–254, 1990.
[85] K. Rosenberg, H. Olsson, M. Mörklin, and D. Heinegård, “Cartilage oligomeric matrix protein shows high affinity zinc-dependent interaction with triple helical collagen,” Journal of Biological Chemistry, vol. 273, no. 32, pp. 20397–20403, 1998.

[86] I. Chan, L. Liu, T. Hamada, G. Sethuraman, and J. A. Mcgrath, "The molecular basis of lipid proteinosis: mutations in extracellular matrix protein 1," Experimental Dermatology, vol. 16, no. 11, pp. 881–890, 2007.

[87] P. E. Di Cesare, F. S. Chen, M. Moergelin et al., “Matrix-cellular matrix protein 1,” Experimental Dermatology, vol. 21, no. 5, pp. 461–470, 2002.

[88] M. D. Briggs and K. L. Chapman, “Pseudoachondroplasia and multiple epiphyseal dysplasia: mutation review, molecular interactions, and genotype to phenotype correlations,” Human Mutation, vol. 19, no. 5, pp. 465–478, 2002.

[89] G. C. Jackson, L. Mittaz-Cretto, J. A. Taylor et al., “Pseudoachondroplasia and multiple epiphyseal dysplasia: a 7-year comprehensive analysis of the known disease genes identify novel and recurrent mutations and provides an accurate assessment of their relative contribution,” Human Mutation, vol. 33, no. 1, pp. 144–157, 2012.

[90] M. Neidhart, N. Hauser, M. Paulsson, P. E. Dicesare, B. A. I. Chan, L. Liu, T. Hamada, G. Sethuraman, and J. A. Mcgrath, "The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse," Osteoarthritis and Cartilage, vol. 15, no. 9, pp. 1061–1069, 2007.

[91] J. Buckland, "Osteoarthritis: positive feedback between ADAMTS-7 and TNF in OA," Nature Reviews Rheumatology, vol. 9, no. 10, p. 566, 2013.

[92] E. Salgado and J. R. Maneiro, "New therapies for rheumatoid arthritis," Medicina Clinica, 2014.

[93] P. Jacques and F. Van den Bosch, "Emerging therapies for rheumatoid arthritis," Expert Opinion on Emerging Drugs, vol. 18, no. 2, pp. 231–244, 2013.

[94] S. S. Náh, S. Lee, J. Joo et al., "Association of ADAMTS12 polymorphisms with rheumatoid arthritis," Molecular Medicine Reports, vol. 6, no. 1, pp. 227–231, 2012.

[95] E. Kudryavtseva, T. S. Forde, A. D. Pucker, and V. A. Adarichev, "Wnt signaling genes of murine chromosome 15 are involved in sex-affected pathways of inflammatory arthritis," Arthritis & Rheumatism, vol. 64, no. 4, pp. 1057–1068, 2012.

[96] C. Barragan-Martinez, J. Amaya-Amaya, R. Pineda-Tamayo et al., "Gender differences in Latin-American patients with rheumatoid arthritis," Gender Medicine, vol. 9, no. 6, pp. 490.e5–510.e5, 2012.

[97] C. Barnabe, L. Bessette, C. Flanagan et al., "Sex differences in pain scores and localization in inflammatory arthritis: a systematic review and metaanalysis," The Journal of Rheumatology, vol. 39, no. 6, pp. 1221–1230, 2012.

[98] T. Furuya, J. L. Salstrom, S. McColl-Vining et al., "Genetic dissection of a rat model for rheumatoid arthritis: significant gender influences on autosomal modifier loci," Human Molecular Genetics, vol. 9, no. 15, pp. 2241–2250, 2000.

[99] M. Brenner, T. Laragione, A. Mello, and P. S. Gulko, "Cia25 on rat chromosome 12 regulates severity of autoimmune arthritis induced with pristane and with collagen," Annals of the Rheumatic Diseases, vol. 66, no. 7, pp. 952–957, 2007.

[100] H.-C. Meng, M. M. Griffiths, E. F. Remmers et al., "Identification of two novel female-specific non-major histocompatibility complex loci regulating collagen-induced arthritis severity and chronicity, and evidence of epistasis," Arthritis and Rheumatism, vol. 50, no. 8, pp. 2695–2705, 2004.

[101] V. A. Adarichev, A. B. Nesterovitch, T. Bárdom et al., "Sex effect on clinical and immunologic quantitative trait loci in a murine model of rheumatoid arthritis," Arthritis and Rheumatism, vol. 48, no. 6, pp. 1708–1720, 2003.

[102] T. T. Glant, S. Szántó, A. Vegvari et al., "Two loci on chromosome 15 control experimentally induced arthritis through the differential regulation of IL-6 and lymphocyte proliferation," Journal of Immunology, vol. 181, no. 2, pp. 1307–1314, 2008.

[103] K. MacKay, S. Eyre, A. Myerscough et al., "Whole-genome linkage analysis of rheumatoid arthritis susceptibility loci in 252 affected sibling pairs in the United Kingdom," Arthritis and Rheumatism, vol. 46, no. 3, pp. 632–639, 2002.

[104] S. Shiozawa, S. Hayashi, Y. Tsukamoto et al., "Identification of the gene loci that predispose to rheumatoid arthritis," International Immunology, vol. 10, no. 12, pp. 1891–1895, 1998.
[115] S. Yamamoto, O. Nishimura, K. Misaki et al., “Cihrc1 selectively activates the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt-receptor complex,” Developmental Cell, vol. 15, no. 1, pp. 23–36, 2008.

[116] Y. Li and A. T. Dudley, “Noncanonical frizzled signaling regulates cell polarity of growth plate chondrocytes,” Development, vol. 136, no. 7, pp. 1083–1092, 2009.

[117] L. Tang, D. L. Dai, M. Su, M. Martinka, G. Li, and Y. Zhou, “Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers,” Clinical Cancer Research, vol. 12, no. 12, pp. 3716–3722, 2006.

[118] Y. Matsumura, M. Matsumura, and K. Ohta, “Local characteristics of allergic diseases: adult asthma in the central area of Tokyo,” Avrugi, vol. 43, no. 11, pp. 1340–1344, 1994.

[119] Y. Ohki, K. Tokuyama, H. Mayuzumi et al., “Characteristic features of allergic airway inflammation in a murine model of infantile asthma,” International Archives of Allergy and Immunology, vol. 138, no. 1, pp. 51–58, 2005.

[120] J. S. Allen, R. Eisima, D. LaFrenciere, G. Leonard, and D. Kreutzer, “Characterization of the eosinophil chemokine rantes in nasal polyps,” Annals of Otolaryngology, Rhinology and Laryngology, vol. 107, no. 5, part 1, pp. 416–420, 1998.

[121] R. G. Stirling, E. L. J. Van Rensen, P. J. Barnes, and K. F. Chung, “Interleukin-5 induces CD34+ eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma,” The American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 8, part 1, pp. 1403–1409, 2001.

[122] B. Stolarski, M. Kurowska-Stolarska, P. Kewin, D. Xu, and F. C. M. Lloyd, “IL-33 family members and asthma—bridging cell polarity of growth plate chondrocytes,” Mediators of Inflammation, vol. 138, no. 1, pp. 51–58, 2000.

[123] K. D. Dyer, C. M. Percopo, and H. F. Rosenberg, “IL-33 promotes eosinophilia in vivo and antagonizes IL-5-dependent eosinophil hematopoiesis ex vivo,” Immunology Letters, vol. 150, no. 1–2, pp. 41–47, 2013.

[124] C.-L. Hsu, C. V. Neilsen, and P. J. Bryce, “IL-33 is produced by mast cells and regulates IgE-dependent inflammation,” PLoS ONE, vol. 5, no. 8, Article ID e11944, 2010.

[125] C. M. Lloyd, “IL-33 family members and asthma—bridging innate and adaptive immune responses,” Current Opinion in Immunology, vol. 22, no. 6, pp. 800–806, 2010.

[126] N. A. Maiani, D. Roos, and T. W. Kuijpers, “Bid truncation, Bid/Bax targeting to the mitochondria, and caspase activation associated with neutrophil apoptosis are inhibited by granulocyte colony-stimulating factor,” Journal of Immunology, vol. 172, no. 11, pp. 7024–7030, 2004.

[127] V. Hvidberg, M. B. Maniecki, C. Jacobsen, P. Hojrup, H. J. Moller, and S. K. Moestrup, “Identification of the receptor scavenging hemepxin-heme complexes,” Blood, vol. 106, no. 7, pp. 2572–2579, 2005.

[128] M. A. Arruda, A. G. Rossi, M. S. De Freitas, C. Barja-Fidalgo, and A. V. Graça-Souza, “Heme induces human neutrophil apoptosis: involvement of phosphoinositide 3-kinase, MAPK, and NF-kB,” Journal of Immunology, vol. 173, no. 3, pp. 2023–2030, 2004.

[129] C. A. Fielding, R. M. McLoughlin, L. McLeod et al., “IL-6 regulates neutrophil trafficking during acute inflammation via STAT3,” Journal of Immunology, vol. 181, no. 3, pp. 2189–2195, 2008.

[130] M. Esteller, “Cancer epigenomics: DNA methylomes and histone-modification maps,” Nature Reviews Genetics, vol. 8, no. 4, pp. 286–298, 2007.

[131] T. Fontanil, S. Rua, M. Llamaza et al., “Interaction between the ADAMTS-12 metalloprotease and fibulin-2 induces tumor-suppressive effects in breast cancer cells,” Oncotarget, vol. 5, no. 5, pp. 1253–1264, 2014.

[132] S. Blacher, M. Jost, L. Melen-Lamalle et al., “Quantification of in vivo tumor invasion and vascularization by computerized image analysis,” Microvascular Research, vol. 75, no. 2, pp. 169–178, 2008.

[133] G. Bernardini, D. Ribatti, G. Spinetti et al., “In vitro and in vivo models to study chemokine regulation of angiogenesis,” Methods in Molecular Biology, vol. 239, pp. 223–232, 2004.

[134] A. I. Olin, M. Mörgelin, T. Sasaki, R. Timpl, D. Heinegård, and A. Aspberg, “The proteoglycans aggrecan and versican form networks with fibulin-2 through their lectin domain binding,” Journal of Biological Chemistry, vol. 276, no. 2, pp. 1253–1261, 2001.

[135] F. Segade, “Molecular evolution of the fibulins: implications on the functionality of the elastic fibulins,” Gene, vol. 464, no. 1-2, pp. 17–31, 2010.

[136] A. J. Obaya, S. Rua, A. Moncada-Pazos, and S. Cal, “The dual role of fibulins in tumorigenesis,” Cancer Letters, vol. 325, no. 2, pp. 132–138, 2012.

[137] G. A. Rosenberg, “Matrix metalloproteinases in neuroinflammation,” Glia, vol. 39, no. 3, pp. 279–291, 2002.

[138] G. A. Rosenberg, “Matrix metalloproteinases and neuroinflammation in multiple sclerosis,” Neuroscientist, vol. 8, no. 6, pp. 586–595, 2002.

[139] H. Konnecke and I. Bechmann, “The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas,” Clinical and Developmental Immunology, vol. 2013, Article ID 914014, 15 pages, 2013.

[140] J. K. Rybakowski, M. Skibinska, P. Kapelski, L. Kaczmarek, and J. Hauser, “Functional polymorphism of the matrix metalloproteinase-9 (MMP-9) gene in schizophrenia,” Schizophrenia Research, vol. 109, no. 1–3, pp. 90–93, 2009.

[141] A. C. Need, D. Ge, M. E. Weale et al., “A genome-wide investigation of SNPs and CNVs in schizophrenia,” PLoS Genetics, vol. 5, no. 2, Article ID e1000373, 2009.

[142] I. N. Bespalova, G. W. Angelo, B. P. Ritter et al., “Genetic variations in the ADAMTS12 gene are associated with schizophrenia in Puerto Rican patients of Spanish descent,” NeuroMolecular Medicine, vol. 14, no. 1, pp. 53–64, 2012.

[143] G.-A. Carré, I. Couty, C. Henequet-Antier, and M. S. Govoroun, “Gene expression profiling reveals new potential players of gonad differentiation in the chicken embryo,” PLoS ONE, vol. 6, no. 9, Article ID e23959, 2011.

[144] J. Zou, “The Characterization of ADAMTS-12 in the Regulation of Human Trophoblast Invasion in vitro,” A Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in the Faculty of Graduate Studies, 2010.

[145] A. G. Beristain, H. Zhu, and P. C. K. Leung, “Regulated expression of ADAMTS-12 in human trophoblastic cells: a role for ADAMTS-12 in epithelial cell invasion?” PLoS ONE, vol. 6, no. 4, Article ID e18473, 2011.

[146] A. Arning, M. Hiersche, A. Witten et al., “A genome-wide association study identifies a gene network of ADAMTS genes in the predisposition to pediatric stroke,” Blood, vol. 120, no. 26, pp. 5231–5236, 2012.

[147] K. Bein and M. Simons, “Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity,” Journal of Biological Chemistry, vol. 275, no. 41, pp. 32167–32173, 2000.